Bruker BRKR Bsi Nano — Goodwill Impairment
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bruker in its filing.
Tagged under the XBRL concept us-gaap:GoodwillImpairmentLoss.
The source filing: Bruker’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:24 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335226
On April 1, 2026, the Company completed the merger of the Bruker Cellular Analysis (“BCA”) business into the Bruker Spatial Biology (“BSB”) division. In connection with this merger, the Company performed a goodwill impairment test for the BSB reporting unit pre‑merger as of March 31, 2026, and for the newly combined BSB reporting unit post‑merger as of April 1, 2026. Based on the results of the post-merger goodwill impairment test, during the three and six months ended June 30, 2026, the Company recorded a goodwill impairment charge of $36.5 million in the unaudited condensed consolidated statements of operations within the BSI NANO segment, which represented the amount by which the carrying value of the post-merger BSB reporting unit exceeded its fair value.
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Bruker's bsi nano — goodwill impairment?
- Bruker (BRKR) reported bsi nano — goodwill impairment of $36.5M in Q2 2026.
- How has Bruker's bsi nano — goodwill impairment changed year-over-year?
- Bruker's bsi nano — goodwill impairment increased by 170.4% year-over-year, from $13.5M to $36.5M.
- What does bsi nano — goodwill impairment mean?
- A non-cash charge recognized when the carrying amount of goodwill in the BSI Nano segment exceeds its implied fair value. It indicates that the expected future economic benefits of past acquisitions have diminished.
Ask your AI about Bruker's bsi nano — goodwill impairment.
Connect your AI assistant and compare segments, right in your chat.
